Dr. Sandipani M. Sandilya, MD

Dr. Sandilya practices at Audie L. Murphy Memorial Veterans' Hospital in San Antonio, Texas, part of Veterans Health Administration.

Dr. Sandilya's NPI, 1821376609, was assigned on July 28, 2011. Dr. Sandilya holds Massachusetts license 1017683.

Dr. Sandilya's primary practice is Audie L. Murphy Memorial Veterans' Hospital, at 7400 Merton Minter Blvd., San Antonio, TX 78229 in Bexar County. The practice phone is (210) 617-5300.

Dr. Sandilya's primary practice is Audie L. Murphy Memorial Veterans' Hospital in San Antonio, Texas, part of Veterans Health Administration. Dr. Sandilya is also affiliated with Lahey Clinic. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Sandilya to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sandilya practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Sandilya's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Sandilya's licenses on file in 2 states: Massachusetts and Connecticut.

CMS data shows 484 Medicare services from Dr. Sandilya across 9 procedure codes in 2024, for 144 Medicare patients. Medicare paid $35,869 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 144 Medicare patients who saw Dr. Sandilya in 2024. The largest group is 75 to 84, with 55 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 4.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sandilya's median patient age at 76, with 48% women.

In 2024, Dr. Sandilya wrote 148 Medicare Part D claims for 74 patients. 94% of them were for generic drugs. CMS names the drug for 85 of them, across 4 drugs with 11 or more claims each, at $761 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Sandilya for performance year 2024, reported through an alternative payment model (APM). Dr. Sandilya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sandilya as offering telehealth.

Dmand AI links 4 papers to Dr. Sandilya, published from 2011 to 2016. Dr. Sandilya's most frequent co-authors are Ladan Golestaneh, MD, Meenakshi Bewtra, MD and Wojciech Blonski, MD, PhD.

CMS Open Payments shows 6 general payments to Dr. Sandilya from 4 drug and device companies from 2016 to 2019. Food and beverage make up the largest share, 98% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $134.